Joaquim Bellmunt
Beth Israel Deaconess Medical Center
725 Papers
5.2K Citations
Joaquim Bellmunt is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Bladder cancer. The author has an hindex of 82, co-authored 660 publications. Previous affiliations of Joaquim Bellmunt include University of Cambridge & Brigham and Women's Hospital.
Chat about Author
Papers
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Matthew D. Galsky,Andrea Necchi,Srikala S. Sridhar,Osamu Ogawa,Natasha Angra,Stephan Hois,Philip He,Dana Ghiorghiu,Joaquim Bellmunt +8 more
TL;DR: Despite high response rates to 1L SoC for locally advanced or metastatic UC chemotherapy (gemcitabine + cisplatin), this paper reported no improvement in response rates for patients who were cis-platin-inel...
4
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
Jorge Ramos,Jonathan Wingate,Roman Gulati,Elizabeth R. Plimack,Lauren C. Harshman,Thomas Powles,Simon J. Crabb,Guenter Niegisch,Joaquim Bellmunt,Sylvain Ladoire,Ugo De Giorgi,Syed A. Hussain,Ajjai Alva,Jack Baniel,Neeraj Agarwal,Jonathan E. Rosenberg,Ulka N. Vaishampayan,Matthew D. Galsky,Evan Y. Yu +18 more
TL;DR: This study identified a high VTE rate (7.6%) and several factors associated with increased risk including non‐urothelial histology, renal dysfunction, and cardiovascular disease and CVD, similar to the findings in metastatic UTT.
4
Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.
Elena Sevillano,Lillian Werner,Dominick Bossé,Aly-Khan A. Lalani,Stephanie A. Wankowicz,Guillermo Velasco,Matthew S. Farina,Kevin Lundgren,Toni K. Choueiri,Aranzazu Gonzalez del Alba,Joaquim Bellmunt +10 more
TL;DR: Advanced UTUC portends a poor prognosis, and most patients cannot receive cisplatin‐based chemotherapy, so a risk score that includes anemia and receipt of cisPlatin helps stratify patients with distant metastasis for inclusion into eventual clinical trials is recommended.
3
Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.
Ignacio Duran,Clara Montagut,Emiliano Calvo,Susana Galtes,Alicia Navarrete,Jesus Rodriguez-Pascual,Manuel Hidalgo,Juan Francisco Rodriguez-Moreno,Antonio Cubillo,Antonia García,Lorena Sanchez,Coral Barbas,Andrea Viqueira,Joaquim Bellmunt +13 more
TL;DR: T and D can be safely combined at reduced doses of both agents with no PK interaction and preliminary antitumor activity has been observed in CRPC patients.
3